Citi Starts Calithera Biosciences (CALA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities climb as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts CALA Hot Sheet
Price: $0.00 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 22 | New: 41
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 22 | New: 41
Join SI Premium – FREE
Citi initiated coverage on Calithera Biosciences (NASDAQ: CALA) with a Buy rating and a price target of $15.00.
For an analyst ratings summary and ratings history on Calithera Biosciences click here. For more ratings news on Calithera Biosciences click here.
Shares of Calithera Biosciences closed at $11.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CIBC Starts Telesat Corp (TSAT) at Outperformer, 'Clearing The Way For Lightspeed'
- Canaccord Starts American Tungsten Corp (TUNG:CN) at Spec. Buy
- BofA Securities Starts Installed Building Products (IBP) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
